Congenital heart disease in pregnancy




The story of congenital heart disease is one of the major successes of medicine in the last 50 years. Heart conditions previously associated with early death are now successfully treated. Many of these women are now in their child-bearing years wishing to have children of their own. All of these women should be offered comprehensive pre-conception counselling by a dedicated multi-disciplinary team. Each woman will present a unique set of cardiac and obstetric challenges that require an individualised assessment of risk and a carefully documented care plan. In this chapter, I describe the most common forms of congenital heart disease and the specific issues that should be assessed before conception. I present a systematic approach to risk stratification and care planning. These lesions range from mild disease with little implications for pregnancy to those with a sizable risk of maternal mortality or complications. I will also discuss fetal risk factors.


Introduction


With the successful repair and palliation of many forms of congenital heart disease in childhood, a growing population of people are now surviving into adulthood with even complex cardiac lesions . These people have a desire to live as ‘normal’ lives as possible, and having children is part of their expectations for the future.


Congenital heart disease is a rare cause of maternal cardiac mortality; however, a large proportion of women attending pre-pregnancy cardiac obstetric clinics have congenital heart disease . The fact that these women have known cardiac disease enables comprehensive pre-conception counselling and optimisation of care to take place . In contrast, many women with acquired heart disease often present for the first time during pregnancy. Unsurprisingly, most maternal cardiac fatalities occur within this group .


It is difficult to establish precisely the extent of maternal morbidity associated with congenital heart disease. In one of the largest studies on cardiac maternal morbidity , congenital heart disease was not labelled as a separate category. The small number of participants with congenital heart disease were listed under those with valve disease. It has been hypothesised that improved pre-conception counselling and antenatal care have led to an improvement in maternal outcomes in congenital heart disease compared with other forms of maternal cardiac disease .


A wide spectrum of congenital heart lesions exists, ranging from the benign lesion with no effect on longevity to life-shortening conditions that may be highly symptomatic. Some women may present with a cardiac lesion that has a unique anatomy and physiology, and therefore preconception advice and management plans must be tailored to the individual patient. It is understandable that the evidence base for practice is rather patchy in this heterogenous population, and many of the treatment recommendations are based on clinical consensus . It is, therefore, essential that these women are cared for by a team of experienced clinicians in a multi-disciplinary environment .




Principles of pre-conception counselling


Preconception counselling should be offered to all women with congenital heart disease who are of child-bearing age. This advice must be given by a specialist multi-disciplinary team with both cardiac and obstetric input. The advice given should be tailored to the unique anatomy and physiology of each particular women. The key components of comprehensive counselling are presented in Table 1 .



Table 1

World Health Organization risk groups for people with congenital heart lesions. a



























































WHO risk group I
No detectable increased risk of maternal mortality, and no or mild increase in morbidity.
Uncomplicated mild lesions.
small patent duct or mild pulmonary stenosis.
Successfully repaired simple lesions.
WHO risk group II (if uncomplicated).
Small increased risk of maternal mortality or moderate increase in morbidity.
Unrepaired atrial septal or ventricular septal defect.
Repaired Tetralogy.
WHO risk group II-III (depends on individual patient).
Lesions with mild ventricular dysfunction.
Native or tissue valve disease (most).
Repaired coarctation.
WHO risk group III
Significantly increased risk of maternal mortality or severe morbidity.
Mechanical valves.
Systemic right ventricle.
Fontan circulation.
People with cyanosis and other complex lesions.
WHO risk group IV
Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated.
Pulmonary hypertension.
Severe systemic ventricular dysfunction.
Severe left heart obstruction (including coarctation).

a Adapted from Thorne et al. ; WHO, World Health Organization.



Several simple scoring systems have been developed to assist clinicians in their attempts to effectively risk stratify women contemplating pregnancy. The most commonly used of these are the Cardiac Disease in Pregnancy (CARPREG) score and the ZAHARA (Zwangerschap bij Aangeboren Hartafwijking) score ( Table 2 ) . Although far from comprehensive, these scoring systems offer additional tools to approximate risk. An alternative scale that is also informative is the modified World Health Organization pregnancy classification. This has four categories of risk from class I (little additional risk from pregnancy) to class IV (pregnancy is extremely high risk and should be considered contraindicated) .



Table 2

Pre-pregnancy counselling check list.





















































Maternal risks
What are the CARPREG, ZAHARA and modified WHO scores?
What is current functional class? Cardiac symptoms?
Is there a risk of arrhythmia?
Are there any pacing or device issues?
Is there a risk of ventricular dysfunction?
Is cyanosis an issue?
Thrombotic and bleeding risks?
Is the pulmonary artery pressure normal?
Are there obstructive lesions?
Is there a risk of coronary ischaemia?
Is there a risk of dissection or aortic rupture?
Is there an increased risk of hypertension?
Are there drugs that need to be changed or discontinued?
Are there other lifestyle issues? Is the patient a smoker?
Are there any specific obstetric risks?
Are there any fertility issues?
Issues about long-term prognosis?
Fetal risks
Risk due to maternal low cardiac output?
Risk due to maternal cyanosis?
Risk due to maternal medication?
Risks due to maternal lifestyle and smoking?
Risk of prematurity or growth restriction?
Genetic and recurrence risks?


Determinants of fetal outcome in congenital heart disease


Most research on congenital heart disease has focused on maternal outcomes in pregnancy. A key determinant of fetal outcome is maintaining maternal health. Some maternal features are a specific risk to the fetus. These include maternal symptoms, cyanosis, anticoagulation, cigarette smoking, multiple gestation and left heart obstruction . In addition, maternal drug treatments may also adversely affect the fetus; the most common of these are oral anticoagulants and beta-blockers . An important component of pre-pregnancy counselling is assessing the potential fetal affects of cardiac drugs. Ideally, women should be taking a minimum number of essential drugs, and, where possible, drugs with safety concerns should have been discontinued or substituted by alternatives.


Risk of recurrence of congenital heart defects in offspring


Many congenital heart defects have a familial basis. The live birth risk of congenital heart disease is 0.8% for the general population ; in mothers with congenital heart disease, this risk is in the region of 3–5% . This average, however, covers a divergent group of conditions. In a few circumstances, an autosomal dominant inheritance pattern exists (with a 50% recurrence risk). This group includes patients with Di George syndrome (22q11 deletion). These women often have conotruncal lesions, including Tetralogy of Fallot and truncus arteriosus. All women with these lesions should be offered genetic testing before pregnancy . Other sub-groups of congenital heart disease have a higher heritability than the average 3–5% value often quoted. These include bicuspid aortic valve disease, atrioventricular septal defect, and atrial septal defect . For all of these conditions, an estimation of recurrence risk should be individualised to the woman’s lesion and their family history. All pregnant women with a personal or partner history of congenital heart disease should be offered a detailed fetal echocardiogram at 16–23 weeks’ gestation .




Principles of pre-conception counselling


Preconception counselling should be offered to all women with congenital heart disease who are of child-bearing age. This advice must be given by a specialist multi-disciplinary team with both cardiac and obstetric input. The advice given should be tailored to the unique anatomy and physiology of each particular women. The key components of comprehensive counselling are presented in Table 1 .



Table 1

World Health Organization risk groups for people with congenital heart lesions. a



























































WHO risk group I
No detectable increased risk of maternal mortality, and no or mild increase in morbidity.
Uncomplicated mild lesions.
small patent duct or mild pulmonary stenosis.
Successfully repaired simple lesions.
WHO risk group II (if uncomplicated).
Small increased risk of maternal mortality or moderate increase in morbidity.
Unrepaired atrial septal or ventricular septal defect.
Repaired Tetralogy.
WHO risk group II-III (depends on individual patient).
Lesions with mild ventricular dysfunction.
Native or tissue valve disease (most).
Repaired coarctation.
WHO risk group III
Significantly increased risk of maternal mortality or severe morbidity.
Mechanical valves.
Systemic right ventricle.
Fontan circulation.
People with cyanosis and other complex lesions.
WHO risk group IV
Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated.
Pulmonary hypertension.
Severe systemic ventricular dysfunction.
Severe left heart obstruction (including coarctation).

a Adapted from Thorne et al. ; WHO, World Health Organization.



Several simple scoring systems have been developed to assist clinicians in their attempts to effectively risk stratify women contemplating pregnancy. The most commonly used of these are the Cardiac Disease in Pregnancy (CARPREG) score and the ZAHARA (Zwangerschap bij Aangeboren Hartafwijking) score ( Table 2 ) . Although far from comprehensive, these scoring systems offer additional tools to approximate risk. An alternative scale that is also informative is the modified World Health Organization pregnancy classification. This has four categories of risk from class I (little additional risk from pregnancy) to class IV (pregnancy is extremely high risk and should be considered contraindicated) .



Table 2

Pre-pregnancy counselling check list.





















































Maternal risks
What are the CARPREG, ZAHARA and modified WHO scores?
What is current functional class? Cardiac symptoms?
Is there a risk of arrhythmia?
Are there any pacing or device issues?
Is there a risk of ventricular dysfunction?
Is cyanosis an issue?
Thrombotic and bleeding risks?
Is the pulmonary artery pressure normal?
Are there obstructive lesions?
Is there a risk of coronary ischaemia?
Is there a risk of dissection or aortic rupture?
Is there an increased risk of hypertension?
Are there drugs that need to be changed or discontinued?
Are there other lifestyle issues? Is the patient a smoker?
Are there any specific obstetric risks?
Are there any fertility issues?
Issues about long-term prognosis?
Fetal risks
Risk due to maternal low cardiac output?
Risk due to maternal cyanosis?
Risk due to maternal medication?
Risks due to maternal lifestyle and smoking?
Risk of prematurity or growth restriction?
Genetic and recurrence risks?


Determinants of fetal outcome in congenital heart disease


Most research on congenital heart disease has focused on maternal outcomes in pregnancy. A key determinant of fetal outcome is maintaining maternal health. Some maternal features are a specific risk to the fetus. These include maternal symptoms, cyanosis, anticoagulation, cigarette smoking, multiple gestation and left heart obstruction . In addition, maternal drug treatments may also adversely affect the fetus; the most common of these are oral anticoagulants and beta-blockers . An important component of pre-pregnancy counselling is assessing the potential fetal affects of cardiac drugs. Ideally, women should be taking a minimum number of essential drugs, and, where possible, drugs with safety concerns should have been discontinued or substituted by alternatives.


Risk of recurrence of congenital heart defects in offspring


Many congenital heart defects have a familial basis. The live birth risk of congenital heart disease is 0.8% for the general population ; in mothers with congenital heart disease, this risk is in the region of 3–5% . This average, however, covers a divergent group of conditions. In a few circumstances, an autosomal dominant inheritance pattern exists (with a 50% recurrence risk). This group includes patients with Di George syndrome (22q11 deletion). These women often have conotruncal lesions, including Tetralogy of Fallot and truncus arteriosus. All women with these lesions should be offered genetic testing before pregnancy . Other sub-groups of congenital heart disease have a higher heritability than the average 3–5% value often quoted. These include bicuspid aortic valve disease, atrioventricular septal defect, and atrial septal defect . For all of these conditions, an estimation of recurrence risk should be individualised to the woman’s lesion and their family history. All pregnant women with a personal or partner history of congenital heart disease should be offered a detailed fetal echocardiogram at 16–23 weeks’ gestation .

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Nov 8, 2017 | Posted by in OBSTETRICS | Comments Off on Congenital heart disease in pregnancy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access